<DOC>
	<DOCNO>NCT00002123</DOCNO>
	<brief_summary>To evaluate safety , tolerance , pharmacokinetics , efficacy delavirdine mesylate ( U-90152S ) combination didanosine ( ddI ) versus ddI alone HIV-positive patient .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Comparative Study Delavirdine Mesylate ( U-90152S ) Combination With Didanosine ( ddI ) Versus ddI Alone HIV-1 Infected Individuals With CD4 Counts &lt; = 300/mm3</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : AZT . Patients must : HIV1 seropositivity . CD4 count &lt; = 300 cells/mm3 . No active acute ( onset within past month ) opportunistic infection active cryptococcosis , pneumocystis carinii , herpes zoster , histoplasmosis , cytomegalovirus ( CMV ) . Consent parent guardian le 18 year age . Understanding potential risk fetus relate study participation . Acceptable medical history , physical exam , EKG , chest xray screening . NOTE : Patients cutaneous Kaposi 's sarcoma require systemic therapy permit . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active tuberculosis sensitive rifampin . Inability swallow numerous tablet . Clinically significant active acute medical problem , include progressive multifocal leukoencephalopathy , lymphoma , malignancy require systemic therapy . Clinically significant hypersensitivity piperazinetype drug ( e.g. , Antepar Stelazine ) . Grade 2 bad baseline organ function . NOTE : Hemophiliacs grade 2 bilirubin , alkaline phosphatase , SGOT , SGPT consider value stable past year . NOTE : Patients suspect Gilbert 's syndrome consider bilirubin grade 2 better . Patients follow prior condition exclude : History pancreatitis within past 2 year . History clinically significant nervous system muscle disease , seizure disorder , AIDS dementia , psychiatric disorder would preclude study compliance . History grade 2 bad peripheral neuropathy . Intolerance ddI previous treat patient . Prior Medication : Excluded : More 4 month total prior ddI . Any prior ddC , d4T , 3TC . Prior nonnucleoside reverse transcriptase inhibitor , include Ldrugs , nevirapine , TIBO , HEPT , delavirdine , atevirdine , alphaAPA . Other investigational antiretroviral medication ( include foscarnet ) immunomodulators ( include interferon ) within 21 day prior initial study drug dose . Prior prophylactic therapeutic HIV1 gp120 160 vaccine . Rifampin , rifabutin , astemizole , loratadine , terfenadine within 21 day prior initial study drug dose . Any unapproved investigational medication indication within 21 day prior initial study drug dose . Required : AZT therapy time prior screening . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1996</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>